argenx

argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases.

The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. FcRn blockade reduces circulating pathogenic IgG autoantibodies.

argenx is evaluating efgartigimod across a broad portfolio of IgG-mediated autoimmune conditions.